Iran War Escalates as US, Houthis Target Ships Near Key Oil Routes 
Asian Currencies Steady as Dollar Holds Firm After U.S. Inflation Data 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
S&P 500 Hits Record High as Soft Inflation Data Eases Fed Rate Hike Fears 
Asian Currencies Steady Ahead of US CPI as Oil Prices Rise 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Oil, Gold Rise as Geopolitical Risks Grip Markets Ahead of U.S. CPI 
KOSPI Eyes Best Weekly Gain Since June as Samsung, SK Hynix Rally 
UK Economy Posts Surprise June Growth as World Cup and Hot Weather Lift Activity 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Oil Prices Rise as Hormuz Tensions Threaten Global Supply 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Wall Street Hits Record High as Softer Inflation Data Eases Fed Rate Hike Fears 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Add as a preferred source on Google
Medicago Inc. has been developing a plant-based vaccine for COVID-19, and for this project, it has teamed up with some companies, including Philip Morris. The World Health Organization recently rejected its vaccine and with this, the Canadian biotechnology company decided to sever ties with the cigarette maker.
According to Bloomberg, Medicago submitted a request for the emergency-use listing of its plant-based COVID-19 vaccine but WHO did not grant its approval earlier this year. It was reported that the reason for the rejection was the biotech firm’s links with the tobacco industry.
Medicago made Covifenz which was dubbed as the first plant-based COVID vaccine in the world. It was jointly developed by Medicago and GlaxoSmithKline but the Canadian government contributed to the funding of its development by providing $173 million. The Canadian biotech firm is also 25% owned by Philip Morris.
However, despite the successful tests and approval from Health Canada, WHO gave the opposite decision; thus, it cannot be shipped anywhere else. This outcome pushed Medicago to drop Philip Morris from the COVID-19 vaccine collaboration.
The company’s move to eject the cigarette maker from the project was highly praised by civil society, and proceeded to plead with all governments to avoid working with tobacco companies in the future.
"Tobacco corporations, vaccines and governments do not mix well and we applaud the expulsion of Philip Morris from the Medicago collaboration," executive director of the non-profit organization Action on Smoking & Health (ASH) Canada, Les Hagen, said in a press release. "Tobacco industry products are responsible for over eight million deaths annually worldwide and tobacco corporations are desperately trying to whitewash their terrible public image by investing in the health sector.”
Hagen added that they are pleased that Canadian governments have decided to not get involved with a company in the tobacco business any longer. He also described the initial partnership as an “unethical and embarrassing collaboration with a tobacco giant."
Corporate Accountability's tobacco campaign director, Daniel Dorado, added, "Now that Philip Morris has been ejected from this collaboration, we urge Canadian governments to fully comply with the treaty by closing the barn door on any future tobacco industry partnerships."
